HOME >> MEDICINE >> NEWS
Drug that curbs nicotine craving may do same for cocaine

l rewards like food or sex, and hence, the person can become addicted.

Mecamylamine blocks the action of nicotine, and potentially cocaine, by lowering the net amount of dopamine available in the brain. While cocaine still boosts available levels of dopamine, its overall amount is decreased because mecamylamine has plugged up some of the nicotinic receptor sites where the brain would naturally be activating its own dopamine.

"In other words, the brain has its own chemical, acetylcholine, that stimulates the release of dopamine. Mecamylamine comes along and occupies some of the nicotinic acetylcholine receptor sites and prevents them from activating dopamine," Rose said. "So the net effect is that less dopamine is being produced, even when cocaine comes along and boosts dopamine levels through a different pathway."

Rose said the person still desires nicotine or cocaine, but the desire is weakened because the brain is no longer being flooded with dopamine.

"Mecamylamine reduces desire, but it doesn't quench it," he said. "Yet given how few medications there are to combat serious addictions, even a medication that reduces craving can be of significant benefit."

Already, mecamylamine has proven to be of significant benefit in helping people quit smoking. In earlier Duke studies, Rose demonstrated that using a patch with nicotine and mecamylamine together helped 40 percent of smokers quit for at least one year, while only 15 percent of smokers were able to do so using the patch alone.

The researchers expect mecamylamine to be approved for smoking cessation sometime this year.

Co-authors of the Duke study include Rose, Tonya Mead, Amir Rezvani, Camille Gallivan and Rita Gross.


'"/>

Contact: Renee Twombly
Twomb001@mc.duke.edu
919-684-4148
Duke University Medical Center
7-Apr-2000


Page: 1 2

Related medicine news :

1. Youki spray curbs spread of superbug MRSA
2. Prevention program curbs drug abuse among middle-school youth
3. Drug combo curbs artery re-closing after some heart attacks
4. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
5. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
6. Animal study shows link between nicotine and atrial flutter
7. Free nicotine patches increase short-term smoking quit rates
8. Brains nicotine receptors also target for anti-depressants
9. Antidepressant may help people stop smoking when used with nicotine patch
10. Majority of cigarettes in the US smoked by nicotine-dependent or psychiatrically ill persons
11. Reduced exposure tobacco products lessen carcinogen exposure, but medicinal nicotine better

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... 30, 2017 , ... According to the American Society of Plastic Surgeons (ASPS), ... the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, ... over the next 8-10 weeks. For anyone considering a hair removal procedure, there are ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a ... “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill ... This conference discusses strategies to prevent readmissions in light of the most recent ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, ... Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx in ... of the study is to determine the dose level ... a planned Phase 3 cardiovascular outcome study. ... collaboration with Novartis to develop and commercialize drugs to ...
(Date:3/29/2017)... QUEBEC CITY , March 29, 2017 /PRNewswire/ ... Food and Drug Administration (FDA) 510(k) clearance for ... launch of this truly personalized orthopaedic restoration. Bodycad ... clearance for a joint reconstruction implant system. ... designed to optimize personalized restoration of the patient,s ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology:
Cached News: